alanine has been researched along with Thrombosis in 23 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thrombocytopenia, though uncommon, was associated with orbofiban use and an increased risk of bleeding, but also death and MI." | 9.12 | Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. ( Aster, RH; Brassard, J; Braunwald, E; Cannon, CP; Charlesworth, A; Cooper, R; McCabe, CH; Scirica, BM; Skene, AM, 2006) |
| "Thrombocytopenia, though uncommon, was associated with orbofiban use and an increased risk of bleeding, but also death and MI." | 5.12 | Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. ( Aster, RH; Brassard, J; Braunwald, E; Cannon, CP; Charlesworth, A; Cooper, R; McCabe, CH; Scirica, BM; Skene, AM, 2006) |
| "The role of two protein C gamma-carboxyglutamic acid domain mutations in familial thrombosis, protein CVermont (Bovill, E." | 3.69 | Molecular mechanism for familial protein C deficiency and thrombosis in protein CVermont (Glu20-->Ala and Val34-->Met). ( Bovill, EG; Long, GL; Lu, D, 1994) |
| " However, should some hospitalized patients have dosage escalation to intermediate dose? Should some be considered for full-dose anticoagulation without a measurable thromboembolic event and how should that anticoagulation be monitored? Should patients receive postdischarge anticoagulation and with what medication and for how long? What thrombotic issues are related to the various medications being used to treat this coagulopathy? Is antiphospholipid antibody part of this syndrome? What is the significance of isolated ischemic stroke and limb ischemia in this disorder and how does this interface with the rest of the clinical and laboratory features of this disorder? The aims of this article are to explore these questions and interpret the available data based on the current evidence." | 2.72 | COVID-19 and Its Implications for Thrombosis and Anticoagulation. ( Berkman, SA; Tapson, VF, 2021) |
| "The results between cancer-activated and tissue factor-activated blood were similar." | 1.34 | Efficacy of anticoagulants and platelet inhibitors in cancer-induced thrombosis. ( Cloonan, ME; DiNapoli, M; Mousa, SA, 2007) |
| "Roxifiban has pharmacokinetic and pharmacodynamic properties believed to be more favorable than the earlier oral agents." | 1.31 | Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancy. ( Billheimer, JT; He, B; Seiffert, D; Spitz, SM; Stern, AM, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (17.39) | 18.7374 |
| 1990's | 3 (13.04) | 18.2507 |
| 2000's | 12 (52.17) | 29.6817 |
| 2010's | 1 (4.35) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Di Perri, G | 1 |
| Berkman, SA | 1 |
| Tapson, VF | 1 |
| Anedda, L | 1 |
| Bianchini, L | 1 |
| Cuzzolin, L | 1 |
| Finco, G | 1 |
| Fanos, V | 1 |
| Marcialis, MA | 1 |
| Kardara, D | 1 |
| Tousoulis, D | 1 |
| Antoniades, C | 1 |
| Koumallos, N | 1 |
| Xaplanteris, P | 1 |
| Kyvelou, SM | 1 |
| Papageorgiou, N | 1 |
| Vasiliadou, C | 1 |
| Vlachopoulos, C | 1 |
| Stefanadis, C | 1 |
| Abrams, CS | 1 |
| Cines, DB | 1 |
| Billheimer, JT | 1 |
| He, B | 1 |
| Spitz, SM | 1 |
| Stern, AM | 1 |
| Seiffert, D | 1 |
| SALZMAN, EW | 1 |
| CHAMBERS, DA | 1 |
| Staelens, S | 1 |
| Hadders, MA | 1 |
| Vauterin, S | 1 |
| Platteau, C | 1 |
| De Maeyer, M | 1 |
| Vanhoorelbeke, K | 1 |
| Huizinga, EG | 1 |
| Deckmyn, H | 1 |
| Scirica, BM | 1 |
| Cannon, CP | 2 |
| Cooper, R | 1 |
| Aster, RH | 1 |
| Brassard, J | 1 |
| McCabe, CH | 1 |
| Charlesworth, A | 1 |
| Skene, AM | 1 |
| Braunwald, E | 1 |
| Cloonan, ME | 1 |
| DiNapoli, M | 1 |
| Mousa, SA | 3 |
| San Miguel Hernández, A | 1 |
| Inglada-Galiana, L | 1 |
| García Iglesias, R | 1 |
| Alonso Castillejos, N | 1 |
| Martín Gil, FJ | 1 |
| Picard, V | 1 |
| Présot, I | 1 |
| Scarabin, PY | 1 |
| Aiach, M | 1 |
| Emmerich, J | 1 |
| Alhenc-Gelas, M | 1 |
| Lu, D | 1 |
| Bovill, EG | 1 |
| Long, GL | 1 |
| Tsutsumi, S | 1 |
| Saito, T | 1 |
| Sakata, T | 1 |
| Mlyata, T | 1 |
| Ichinose, A | 1 |
| Ogawa, T | 1 |
| Sugidachi, A | 1 |
| Naganuma, H | 1 |
| Asai, F | 1 |
| Hayler, J | 1 |
| Kane, PD | 1 |
| LeGrand, D | 1 |
| Lugrin, F | 1 |
| Menear, K | 1 |
| Price, R | 1 |
| Allen, M | 1 |
| Cockcroft, X | 1 |
| Ambler, J | 1 |
| Butler, K | 1 |
| Dunnet, K | 1 |
| Mitchelson, A | 1 |
| Talbot, M | 1 |
| Tweed, M | 1 |
| Wills, N | 1 |
| Abulencia, JP | 2 |
| Tien, N | 1 |
| McCarty, OJ | 2 |
| Plymire, D | 1 |
| Konstantopoulos, K | 2 |
| Turner, NA | 1 |
| Shields, DC | 1 |
| Fitzgerald, AP | 1 |
| O'Neill, PA | 1 |
| Muckian, C | 1 |
| Kenny, D | 1 |
| Moran, B | 1 |
| Byrne, CE | 1 |
| Fitzgerald, DJ | 1 |
| Ireland, H | 1 |
| Lane, DA | 1 |
| Thompson, E | 1 |
| Walker, ID | 1 |
| Blench, I | 1 |
| Morris, HR | 1 |
| Freyssinet, JM | 1 |
| Grunebaum, L | 1 |
| Olds, R | 1 |
| Thein, SL | 1 |
| Perry, DJ | 1 |
| Harper, PL | 1 |
| Fairham, S | 1 |
| Daly, M | 1 |
| Carrell, RW | 1 |
| Sakata, Y | 1 |
| Smith, GF | 1 |
| Murray, M | 1 |
3 reviews available for alanine and Thrombosis
| Article | Year |
|---|---|
COVID-19 and Its Implications for Thrombosis and Anticoagulation.
Topics: Adenosine Monophosphate; Alanine; Ambulatory Care; Antibodies, Antiphospholipid; Antibodies, Monoclo | 2021 |
What if COVID-19 affects the child: which weapons and how to use them.
Topics: Adenosine Monophosphate; Adolescent; Age Factors; Alanine; Antibodies, Monoclonal, Humanized; Antico | 2021 |
Platelet glycoprotein IIb/IIIa inhibitors and thrombocytopenia: possible link between platelet activation, autoimmunity and thrombosis.
Topics: Abciximab; Alanine; Antibodies, Monoclonal; Autoimmunity; Benzamidines; Humans; Immunoglobulin Fab F | 2002 |
2 trials available for alanine and Thrombosis
| Article | Year |
|---|---|
Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial.
Topics: Aged; Alanine; Angina, Unstable; Aspirin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; | 2006 |
The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists.
Topics: Alanine; Coronary Disease; Genotype; Glycoproteins; Hemorrhage; Humans; Myocardial Infarction; Myoca | 2002 |
18 other studies available for alanine and Thrombosis
| Article | Year |
|---|---|
The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infection
Topics: Adenosine Monophosphate; Alanine; Anticoagulants; Antiviral Agents; Biomarkers; Coronavirus Infectio | 2020 |
Effects of the Ala379Val polymorphism of lipoprotein-associated phospholipase A2 on thrombosis and inflammation in hypertensive patients.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Alanine; Fibrinogen; Gene Frequency; Genotype; Heter | 2011 |
Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancy.
Topics: Alanine; Amidines; Benzodiazepines; Blood Platelets; Humans; In Vitro Techniques; Isoxazoles; Oximes | 2002 |
INHIBITION OF ADP-INDUCED PLATELET AGGREGATION BY SUBSTITUTED AMINO-ACIDS.
Topics: Adenine Nucleotides; Adenosine Diphosphate; Alanine; Alkylation; Amino Acids; Aminocaproates; Aminoc | 1964 |
Paratope determination of the antithrombotic antibody 82D6A3 based on the crystal structure of its complex with the von Willebrand factor A3-domain.
Topics: Alanine; Antibodies; Antibodies, Monoclonal; Antigens; Binding Sites; Binding Sites, Antibody; Blott | 2006 |
Efficacy of anticoagulants and platelet inhibitors in cancer-induced thrombosis.
Topics: Alanine; Cell Line, Tumor; Drug Therapy, Combination; Enoxaparin; Heparin, Low-Molecular-Weight; Hum | 2007 |
[Soluble CD40 ligand: a potential marker of cardiovascular risk].
Topics: Abciximab; Acute Coronary Syndrome; Alanine; Angina, Unstable; Animals; Antibodies, Monoclonal; Anti | 2007 |
Antithrombin Cambridge II (A384S): prevalence in patients of the Paris Thrombosis Study (PATHROS).
Topics: Alanine; Antithrombin III; Case-Control Studies; Humans; Mutation; Paris; Serine; Thrombosis | 2007 |
Molecular mechanism for familial protein C deficiency and thrombosis in protein CVermont (Glu20-->Ala and Val34-->Met).
Topics: Alanine; Base Sequence; DNA Primers; Glutamic Acid; Humans; Methionine; Molecular Sequence Data; Mut | 1994 |
Genetic diagnosis of dysplasminogenemia: detection of an Ala601-Thr mutation in 118 out of 125 families and identification of a new Asp676-Asn mutation.
Topics: Adult; Alanine; Asparagine; Aspartic Acid; Female; Genetic Testing; Humans; Male; Mutation; Phenylal | 1996 |
Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs.
Topics: Adenosine Diphosphate; Administration, Oral; Alanine; Animals; Arteriovenous Shunt, Surgical; Aspiri | 2000 |
The design and synthesis of thrombin inhibitors: the introduction of in vivo efficacy and oral bioavailability into benzthiazolylalanine inhibitors.
Topics: Administration, Oral; Alanine; Animals; Antithrombins; Biological Availability; Chymotrypsin; Drug D | 2000 |
Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis.
Topics: Abciximab; Alanine; Antibodies, Monoclonal; Cell Line; Drug Evaluation, Preclinical; Flow Cytometry; | 2001 |
Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis.
Topics: Alanine; Amidines; Blood Platelets; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; I | 2002 |
Antithrombin Glasgow II: alanine 382 to threonine mutation in the serpin P12 position, resulting in a substrate reaction with thrombin.
Topics: Adult; Alanine; Antithrombin III; Electrophoresis, Polyacrylamide Gel; Female; Humans; Male; Middle | 1991 |
Antithrombin Cambridge, 384 Ala to Pro: a new variant identified using the polymerase chain reaction.
Topics: Adult; Alanine; Antithrombin III; Base Sequence; Chromatography; DNA; DNA-Directed DNA Polymerase; E | 1989 |
[Abnormal plasminogen and thrombosis].
Topics: Adult; Alanine; Amino Acid Sequence; Fibrinolysis; Humans; Isoelectric Focusing; Male; Plasminogen; | 1987 |
Thrombosis and blood coagulation. A study by quantitative N-terminal amino acid analysis.
Topics: Alanine; Amino Acids; Animals; Aspartic Acid; Autoanalysis; Binding Sites; Blood Coagulation; Cattle | 1970 |